Want to join the conversation?
$CELG's second pivotal trial CD-003 will initiate in a staggered parallel fashion early in 2016 and completion timing is similar to that of CD-002. The endoscopy study CD-001 is actively enrolling and the company expects to complete enrollment by year-end 2015. This study has an off-drug observation period up to 52 weeks.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.